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Abstract
Background: Since 1980s the application of Prostate specific antigen (PSA) brought the revolution in prostate cancer
diagnosis. However, it is important to underline that PSA is not the ideal screening tool due to its low specificity, which
leads to the possible biopsy for the patient without High-grade prostate cancer (HGPCa). Therefore, the aim of this
study was to establish a predictive nomogram for HGPCa in patients with PSA 4–10 ng/ml based on Prostate Imaging
Reporting and Data System version 2 (PI-RADS v2), MRI-based prostate volume (PV), MRI-based PV-adjusted Prostate
Specific Antigen Density (adjusted-PSAD) and other traditional classical parameters.
Methods: Between January 2014 and September 2015, Of 151 men who were eligible for analysis were formed the
training cohort. A prediction model for HGPCa was built by using backward logistic regression and was presented on a
nomogram. The prediction model was evaluated by a validation cohort between October 2015 and October 2016
(n = 74). The relationship between the nomogram-based risk-score as well as other parameters with Gleason
score (GS) was evaluated. All patients underwent 12-core systematic biopsy and at least one core targeted biopsy
with transrectal ultrasonographic guidance.
Results: The multivariate analysis revealed that patient age, PI-RADS v2 score and adjusted-PSAD were independent
predictors for HGPCa. Logistic regression (LR) model had a larger AUC as compared with other parameters alone. The
most discriminative cutoff value for LR model was 0.36, the sensitivity, specificity, positive predictive value and negative
predictive value were 87.3, 78.4, 76.3, and 90.4%, respectively and the diagnostic performance measures retained similar
values in the validation cohort (AUC 0.82 [95% CI, 0.76–0.89]). For all patients with HGPCa (n = 50), adjusted-PSAD and
nomogram-based risk-score were positively correlated with the GS of HGPCa in PSA gray zone (r = 0.455, P = 0.002 and
r = 0.509, P = 0.001, respectively).
Conclusion: The nomogram based on multiparametric magnetic resonance imaging (mp-MRI) for forecasting HGPCa
is effective, which could reduce unnecessary prostate biopsies in patients with PSA 4–10 ng/ml and nomogram-based
risk-score could provide a more robust parameter of assessing the aggressiveness of HGPCa in PSA gray zone.
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Background
Prostate cancer (PCa) is the third leading cause of can-
cer death among men worldwide [1]. The introduction
of prostate-specific antigen (PSA) in selecting men for
prostate biopsy leads to earlier detection of prostate can-
cer (PCa) and, perhaps, a reduction in PCa-specific mor-
tality [2]. However, there has been a steady rise in the
detection of low-grade PCa (commonly referred to as
over-diagnosis) and subsequent overtreatment [3]. This
problem is attributable to the poor sensitivity and speci-
ficity profile of PSA. This is particularly the case in a
PSA gray zone (4–10.0 ng/ml), at which 65–70% of men
have a negative biopsy result [4]. Men with indolent disease
who undergo treatment may experience complications
without reducing their risk of dying from PCa [5].
Some PSA evolutional indexes are widely used clinic-
ally, such as free/total PSA ratio (PSA f/t ratio) and PSA
density (PSAD). However, they are all provincial because
of their dependence on PSA [6]. Furthermore, several
other advanced attempts have been performed, such as
4 K score [7] and messenger RNA (mRNA) [8]. Though
these models based on these new tests might be useful,
the unavailable parameters limit the application. Now-
adays, the growing availability of Multiparametric magnetic
resonance imaging (mp-MRI) and increased standardisa-
tion has increased the role of prostate MRI in detecting of
prostate cancer [9]. Prostate Imaging Reporting and Data
System version 2 (PI-RADS v2), which was released online
in the form of a 55-page document in December 2014, the
overall five-point scale used in PI- RADS v2 is not designed
for every cancer but for high-grade prostate cancer
(HGPCa) that may require further work-up or target bi-
opsy [10]. Therefore, the aim of this study was to develop
a model combining prostate mp-MRI with traditional clin-
ical risk factors that could be used to identify patients ac-
curately with HGPCa (Gleason score ≥ 7) on reduction of
unnecessary prostate biopsies in PSA gray zone.
Methods
Subjects
The retrospective study was approved by the regional
ethical board of the Affiliated Hospital of Chengdu Uni-
versity. Informed written consent was obtained from all
subjects prior to inclusion in the study. Inclusion criteria
were suspicion of PCa owing to increased PSA levels
combined with a suspicious abnormality at MR imaging
eligible for target biopsy (TB) and available clinical data
such as PSA level, DRE and TRUS results. Exclusion cri-
teria were as follows: the patient had a history of pros-
tate biopsy, the patient had benign prostatic hypertrophy
treated with a 5a-reductase inhibitor, and the patient
had a contraindication to transrectal US-guided biopsy
(eg, anorectal stenosis). Two temporally separated pa-
tient cohorts were identified: January 2014 to September
2015 (training cohort) and October 2015 to October
2016 (validation cohort). In total, 225 consecutive patients
with prebiopsy PSA between 4 ng/ml and 10 ng/ml were
finally enrolled for evaluation.
MRI protocol
Subjects underwent mp-MRI using a 3.0 T MR imager
(Tim Trio, Siemens Healthcare, Erlangen, Germany) with a
six-channel phased-array body coil. To suppress bowel
peristalsis all patients received 20 mg butylscopolamine
(Buscopan; Boehringer, Ingelheim, Germany) intravenously.
The main imaging protocols included high-resolution axial
T2WI, DWI, and DCE-MRI. An axial fat saturation T2W
turbo spin echo (TSE) sequence (TR/TE, 4000/100 ms;
slice thickness, 3 mm; no interslice gap; echo train length,
23; averages, two; field of view [FOV], 200 × 200 mm) were
acquired. Diffusion-weighted imaging (DWI) was acquired
using a single-shot echoplanar imaging (EPI) sequence. The
slice thickness was 3.0 mm with no intersection gap, matrix
size 128 × 128, and the FOV 260 × 210 mm. The TR/TE
3700/80 ms, flip angle 90°, averages 6, with three b values
of 0, 100, and 1000 s/mm2 . ADC maps were then automat-
ically generated on the basis of a voxelwise calculation.
DCE was performed with a 3D spoiled gradient-echo se-
quence with TR/TE = 5/1.69 ms, flip-angle = 12°, FOV
260 × 260 mm, slice thickness was 3.0 mm with no
interslice gap, temporal resolution = 5.7 s seconds, and
32 contrast-enhanced sets of images were acquired se-
quentially. The data acquisition of the dynamic contrast-
enhanced images began simultaneously with the initiation
of IV bolus administration of gadopentetate dimeglumine
(Magnevist; Berlex, Wayne, NJ) at a flow rate of 4 ml/s,
followed by a flush of 20 ml of saline solution.
Prostate volume estimation
The method for estimation of the total prostate volumes
from T2-weighted MR images was reported previously
[11] and the ITK-SNAP software (Penn Image Comput-
ing and Science Laboratory) was adapted for this manual
correction task. Briefly, the entire prostate was semiau-
tomatically segmented on T2-weighted MR images [12]
and a radiologist (5 years experience in prostate MRI)
reviewed and manually corrected the segmentation results,
especially at the base and the apex of the prostate, to ensure
accuracy. Finally, the adjusted-PSAD was calculated by div-
iding PSA concentration by the MR-based prostate volume.
MR image analysis
Two urogenital radiologists (3 and 5 years of experience,
respectively, in prostate imaging) reviewed the images in
consensus at a standard Picture Archive and Communica-
tion System (PACS) workstation ((Syngo, Siemens Health-
care, Erlangen, Germany). These two readers whom were
blinded to initial mp-MR imaging reports and resultant
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clinical-pathologic outcomes, scored the examinations.
The PI-RADS v2 scores were assessed on each of the se-
quences of T2WI, DWI, and DCE-MRI in turn to provide
the overall PI-RADS v2 score [13]. If there were multiple
lesions, the PI-RADS v2 score of the index lesion demon-
strating the largest size or the most aggressive feature (i.e.,
extracapsular extension) was assigned to the patient.
Biopsy procedure and Histopathology
At time of biopsy, first, standardized 12-core transrectal
US-guided systematic biopsy was performed by a urolo-
gist (who had 4 years of experience with prostate biopsy).
Next, targeted biopsy was performed by same operator;
these biopsies consisted of at least one additional core per
target, the TB were using cognitive registration (cognitive
TB [TB-COG]) on the basis of zonal anatomy or imaging
landmarks (eg, cysts, remarkable nodules), which was de-
scribed in a previously published studies [14, 15]. All bi-
opsy cores were immediately fixed in formalin, stained
with haematoxylin and eosin (H&E) and underwent rou-
tine histopathological evaluation. A Gleason score of ≥ 7
were defined as ‘high-grade prostate cancer’.
Statistical analysis
As a primary analysis, we considered the statistical asso-
ciations between the mp-MRI and clinical data with the
binary outcome of HGPCa (present/absent). The data
were presented as median (interquartile range) or mean
(standard deviation), as appropriate. For comparison of
continuous variables, the Welch t test was used or the
Mann-Whitney-Wilcoxon test as a nonparametric alter-
native. A chi-square or Fisher exact test was applied to
compare proportions.
Univariate and multivariate analyses were performed
using logistic regression analysis to determine significant
predictors of HGPCa. Odd ratios and 95% CIs were deter-
mined. The Hosmer-Lemeshow goodness-of-fit test was
used to test the quality of the fitted model to the observed
data, with a result of p > 0.05 considered a good fit. The
area under the receiver operating characteristic curve was
used to evaluate each predictor and how the model can
allow discrimination between patients with and without
HGPCa. Area under the curve (AUC) was compared
against each other using the DeLong method to determine
if a significant difference was present. The statistical ana-
lysis was performed using STATA version 9.0 (StataCorp
LP, College Station, TX) and Medcalc 15.8 (Medcalc
Software bvba, Ostend, Belgium). The nomogram was
generated using the R software package (http://
www.r-project.org/). An association between the
nomogram-based risk-score as well as other parame-
ters with Gleason score (GS) of HGPCa was tested by
the Spearman rank correlation analysis. To further evalu-
ate the model’s performance, the nomogram-generated
probability was calculated for every patient in the valid-
ation cohort then compared with pathology outcomes. A
p < 0.05 was considered to indicate statistical significance.
Results
Patients demographics
For the training cohort, 67 patients (44%) were negative
for PCa (benign lesions). Biopsy revealed high-grade PCa
in 32 patients (21%) and low-grade PCa in 52 patients
(35%). Gleason Score distribution of training cohort was
as follows: 3 + 3 = 6 (52 patients), 3 + 4 = 7 (6 patients), 4 +
3 = 7 (8 patients), 4 + 4 = 8 (6 patients), 4 + 5 = 9 (4 patients),
5+ 4 = 10 (4 patients) and 5+ 5 = 10 (4 patients). For the val-
idation patient cohort, 36 of the 74 (48%) were classified as
benign lesions. Biopsy revealed high-grade PCa in 18 pa-
tients (24%) and low-grade PCa in 20 patients (28%).
Gleason Score distribution of validation cohort was as
follows: 3 + 3 = 6 (20 patients), 3 + 4 = 7 (4 patients), 4 + 3 =
7 (3 patients), 4 + 4 = 8 (3 patients), 4 + 5 = 9 (4 patients),
5 + 4 = 9 (2 patients) and 5 + 5 = 9 (2 patients). Patient
characteristics are detailed in Table 1. The baseline
characteristics showed no statistically significant differ-
ences between both cohorts.
Construction of LR model
The univariate logistic regression analysis showed that
patient age, PSA f/t ratio, MRI-based PV, adjusted-
PSAD, and PI-RADS v2 score were significant predictors
of HGPCa in the training cohort. The multivariate logis-
tic regression analysis revealed that the age, PI-RADS v2
score and adjusted-PSAD were independent predictors
of HGPCa (Table 2). The cut-off value of the logit was
determined based on the ROC curve in consideration of
an appropriate tradeoff between the sensitivity and spe-
cificity. At the cut-off value of 0.36, i.e., the estimated
present of HGPCa before biopsy in this cohort, sensitiv-
ity and specificity were 87.3% and 78.4%, respectively
(Fig. 1). In addition, the results of the Hosmer-Lemeshow
test, which showed a x2 value of 2.19 (p = 0.31), indicated
that the model is almost good fit. For all patients with
HGPCa (n = 50), adjusted-PSAD and nomogram-based
risk-score were positively correlated with the GS of
HGPCa (r = 0.455, P = 0.002 and r = 0.509, P = 0.001, re-
spectively), while other parameters found no correlation
with GS of HGPCa (Fig. 2) in PSA gray zone.
Validation of LR model
The results of ROC-AUC analysis for training set, com-
pare with other parameters are shown in Table 3. The
highest AUC for a single risk factor is PI-RADS v2 score
(AUC = 0.76). It is notable that in ROC curves, our new
model had a larger AUC as compared with other param-
eters alone. A nomogram was developed using these
three independent risk factors (patient age, PI-RADS v2
Niu et al. BMC Medical Imaging  (2017) 17:11 Page 3 of 9
score and adjusted-PSAD) to forecast HGPCa (Fig. 3).
Sample case of the diagnostic use of the nomogram is
given in Fig. 4. In validation set, the AUC of the classi-
fier was 0.82 (95% CI, 0.76–0.89), the sensitivity 85.1%
and the specificity 76.3%.
Discussion
In the PSA gray zone there is still the problem of how to
separate the patients who have HGPCa from those who
don’t have it. The positive biopsy rate in the diagnostic
gray zone of PSA 4–10 ng/ml has been shown to vary
across different ethnic groups and countries [16]. In our
study, we also proved that the performance of PSA in
predicting HGPCa with PSA 4–10 ng/ml was poor
(AUC = 0.54). Notably, in these kinds of patient groups
up to 80% of biopsies were unnecessary, and therefore, a
better risk prediction method specific to these patients is
needed.
MRI became the method of choice for detection and
staging of PCa [17]. In response, the European Society of
Table 1 Descriptive characteristics of the study population
Variable Training cohort Validation cohort p value
Patients, n 151 74 NA
Age, yr,
(median; IQR)
63.5; 65–74 64.9;62–73 0.26
tPSA, ng/ml,
(median; IQR)
5.7; 4.8–6.7 5.3; 4.2–6.6 0.30
fPSA, ng/ml,
(median; IQR)
1.12; 0.41–3.39 1.16; 0.32–4.17 0.21
PSA f/t,
(median; IQR)
0.13; 0.06–0.44 0.17; 0.09–0.52 0.16
MRI-based PV, cm3
(median; IQR)
46.2; 36.4–59.4 48.2; 33.7–58.1 0.32
Adjusted PSAD, ng/ml/cm3, mean (median; IQR) 0.17; 0.12–0.53 0.16; 0.06–0.47 0.71
DRE nodules
yes/no, n (%)
86 (57) / 65 (43) 44 (59) / 30 (41) 0.46
TRUS,
Hypoechoic (positive)/Isoechoic (negative)
81 (53) / 70 (47) 42 (56) / 32 (44) 0.56
PI-RADS v2 scores, mean (± SD) 3.3 (±0.9) 3.1 (±1.0) 0.50
Pathological outcomes, n (%)
High-grade cancer 32 (21) 18 (24) 0.80
Low-grade cancer 52 (35) 20 (28)
Benign 67 (44) 36 (48)
IQR Interquartile range, SD Standard deviation, NA Not available, PSA Prostate-specific antigen, MRI Magnetic resonance imaging, PV Prostate volume,
PSAD Prostate-specific antigen density, DRE Digital rectal examination, TRUS Transrectal ultrasound, PI-RADS v2 Prostate Imaging Reporting and Data System version 2
Table 2 Univariate and multivariate logistic regression analyses to detect clinically significant prostate cancer
Predictor Univariate analysis Multivariate analysis
OR (95% CI) p value OR (95% CI) p value
Age 1.040 (0.893–2.089) 0.021 1.074 (1.008–1.243) 0.031
tPSA 0.040 (0.012–0.089) 0.238 NA
fPSA 1.342 (0.712–1.993) 0.413 NA
PSA f/t 1.772 (0.832–2.116) 0.043 NA
NA
NA
MRI-based PV 1.112 (1.069–1.157) 0.011 NA
Adjusted PSAD 6.433 (4.293–8.140) <0.001 4.711 (3.704–6.313) 0.013
DRE results 0.547 (0.199–1.639) 0.078 NA
TRUS results 0.961 (0.370–1.826) 0.069 NA
PI-RADS v2 scores 3.231 (2.173–6.804) <0.001 2.171 (1.345–3.504) <0.001
OR odds ratio, CI confidence interval, NA Not available, PSA Prostate-specific antigen, MRI Magnetic resonance imaging, PV Prostate volume, PSAD Prostate-specific
antigen density, DRE Digital rectal examination, TRUS Transrectal ultrasound, PI-RADS v2 Prostate Imaging Reporting and Data System version 2
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Fig. 1 Plot of sensitivity and specificity for logistic regression model. Plot of sensitivity (red line) and specificity (blue line) as a function of the
probability cut points obtained from the logistic model for diagnosising of high-grade prostate cancer. The optimal probability cutoff point was
determined to be 0.36
Fig. 2 Relationship between all parameters and Gleason scores. Statistically positive correlation were observed between adjusted-PSAD, nomogram-
based risk-score with the GS of HGPCa (r = 0.455, P = 0.002 and r = 0.509, P = 0.001, respectively), while other parameters found no correlation with GS
of HGPCa in PSA gray zone
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Urogenital Radiology (ESUR) drafted guidelines, which
have been updated to the PI-RADS v2 recently, by a
steering committee including the American College of
Radiology (ACR), ESUR and the AdMeTech Foundation
[18]. This version assesses the likelihood (probability) of
HGPCa and maybe useful for suggesting appropriate pa-
tients to active surveillance on a 5-point scale [19]. A
meta-analysis that assessed the performance of mp-MRI
for detecting prostate cancer demonstrated specificity of
0.88 (95% CI, 0.82–0.92), sensitivity of 0.74 (95% CI,
0.66–0.81) and NPV of 0.64–0.94 [20]. Park et al. [10]
reported that the use of PI-RADS v2 might help pre-
operatively diagnose HGPCa (Sensitivity and specificity
were 77.0 and 73.8%, respectively), while, Washino et al.
[21] reported that although the PI-RADS score predicts
biopsy outcome well, it is difficult to decide which patients
can avoid unnecessary prostate biopsies using only the
PI-RADS score because of the relatively low PPV.
Through the result of these studies, a model was de-
veloped combining PI-RADS v2 score, PSA level, MRI-
based PV, adjusted-PSAD, and PSA-related evolutional
markers with other independent risk factors, such as
age, DRE and TRUS results, into one logistic regression
model. The present study shows the AUC of ROC curve
for each univariate variable in predicting a biopsy results.
PI-RADS v2 score were relatively more important for
forecasting HGPCa and were a significant predictor for
HGPCa. Compared with PI-RADS v2 score and adjusted-
PSAD alone, our newly developed model enlarged AUC
from 0.76, 0.74 to 0.85 separately, showing the accuracy
for predicting HGPCa was substantially improved. Not-
ably, Given high NPV (90.4%) in this present study, that is
Table 3 Diagnostic performance of the LR model with other parameters for predicting high grade prostate cancer
Predictor Area under the Curve (95% CI) Threshold Sensitivity (%) Specificity (%) PPV NPV p value
LR model 0.85 (0.79–0.90) >0.36 87.3 78.4 76.3 90.4 (−)
Age (year) 0.63 (0.50–0.67) >71.2 72.7 59.4 58.4 73.4 <0.001
tPSA (ng/ml) 0.54 (0.48–0.67) >7.4 61.2 52.9 51.3 63.5 <0.001
fPSA (ng/ml) 0.52 (0.51–0.69) >2.1 61.7 60.4 59.4 63.4 <0.001
PSA f/t 0.66 (0.61–0.74) >0.18 61.1 69.9 59.2 72.9 <0.001
MRI-based PV (cm3) 0.64 (0.54–0.72) <39.4 70.1 60.9 58.8 72.2 <0.001
Adjusted PSAD
(ng/ml/cm3)
0.74 (0.66–0.79) >0.16 77.2 60.3 59.3 78.6 0.013
DRE results 0.61 (0.57–0.72) NA 65.3 59.4 61.5 67.3 <0.001
TRUS results 0.54 (0.51–0.64) NA 64.1 53.9 51.2 67.9 <0.001
PI-RADS v2 scores 0.76 (0.71–0.84) >3 78.5 74.2 72.8 79.2 0.018
LR Logistic regression, PSA prostate-specific antigen, MRI Magnetic resonance imaging, PV Prostate volume, PSAD Prostate-specific antigen density, DRE Digital
rectal examination, TRUS transrectal ultrasound, PI-RADS v2 Prostate Imaging Reporting and Data System version 2, PPV Positive predictive value, NPV Negative
predictive value
Fig. 3 Nomogram shows logistic model for prediction of high-grade prostate cancer. Predictive nomogram for high-grade cancer incorporating
age, PI-RADS v2 score, adjusted PSAD. Draw a line upward to number of points in each category. Sum the points and draw a line downward to
find the risk of a positive biopsy
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to say if the patient’s LR model risk rate blow 0.36, it could
be used to reliably rule out HGPCa, obviating the biopsy
procedure.
PSA-related evolutional markers including tPSA, PSA
f/t ratio are not sufficiently reliable to allow clinical deci-
sion making in individual patients [22], which comparable
with our results (AUC for PSA f/t ratio was 0.66). The jus-
tification for PSAD evaluation was elaborated in some
previous study, where it was stated that such marker is
better predictor for PCa then PSA level particularly with
4–10 ng/ml [23, 24]. In contrast, our adjusted-PSAD has
higher AUC than previous studies. Traditionally, PSA
“density,” whereby the PSA value is divided by the prostate
volume, estimated from either DRE or TRUS. MRI pro-
vides soft-tissue contrast resolution superior to that of
transrectal ultrasound so that it can be used for more ac-
curate estimation of prostate volume [25, 26]. Therefore,
it is not surprising that the adjusted-PSAD increased the
predictive ability of HGPCa and also became a significant
predictor for HGPCa.
In current study, although our developed new LR
model has achieved high diagnostic performance in de-
tection of HGPCa, the source of false positive and false
negative errors should be addressed. Lesion located in
PZ, especially central zone (CZ) may not be optimally
evaluated using current PZ and TZ criteria. Also, because
the CZ commonly exhibits restricted diffusion that is
similar in extent to that of tumors, that may potentially
yield false-positive or false-negative results. The PZ in
men with diffuse prostatitis or marked BPH often ex-
hibits diffusely altered signal characteristics on various
sequences, which may pose a diagnostic challenge and
yield more false-positive or false-negative results. Fur-
thermore, one particular aspect of PI-RADS v2 for
which we have noted particular variability in reader in-
terpretations is scoring of DCE-MRI in PZ of prostate
lesions. For example, what exactly constitutes early en-
hancement and enhancement that is focal and that
matches an abnormality on other sequences is unclear.
Therefore, once PI-RADS v2 can be applied in a
Fig. 4 A patient with PSA of 8.6 ng/ml, TRUS-guided biopsy revealed a Gleason 4 + 5 = 9 tumour; (a) Labeled segmentation result of entire prostate is
seen on T2-weighted axial image by using ITK-SNAP software (Penn Image Computing and Science Laboratory). Based on the segmentation results,
the total gland is measured 34 cm3 in volume. b DWI with b = 1000 and (c) ADC map show a focal area of diffusion restriction, measuring 1.1 cm in
the longest diameter, in the right peripheral zone (white arrow). The PI-RADS version 2 score of the DWI-ADC was 4 according to both readers,
which is suggestive of a high probability of high-grade cancer cancer. d Nomogram for this patient. The corresponding points of the parameters
(age, 70 years = 41 points [green line]; PI-RADS v2 score, 4 = 32 points [yellow line]; adjusted PASD 0.25 = 50 points [blue line]) yields a total of 123
points. According to nomogram, his probability of having high-grade cancer is 0.53 [red line]. Because probability of greater than 0.36 was defined as
being compatible with high-grade cancer, nomogram allowed correct prediction of high-grade cancer
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consistent fashion across practices, the system will provide
a powerful mechanism for accumulating multicenter data
to optimally address these false positive and false negative
errors that may change current paradigms for prostate
cancer management.
A higher AUC of 0.90 (95% CI, 0.83–0.96) was reported
by a study combining traditional clinical risk factors and
mRNA levels (HOXC6 and DLX1) to derive a logistic re-
gression model based on a large sample (n = 905) [8].
However, to date, only a few biomarkers have reached
clinical practice. The main challenge is to validate the per-
formance of the biomarkers in a clinical cohort independ-
ently and to demonstrate the clinical utility clearly [27].
Fang et al. [28] developed a ‘PAMD’ score which based on
mp-MRI to categorize patients into three risk groups, and
the model showed good predictive accuracy for HGPCa
(AUC = 0.824). In their study, the prostate volume was
determined by TRUS, and the results was not proved
by validation cohort.
Histopathologically, the Gleason grading correlates with
patient outcome, with higher Gleason scores (GS) indicat-
ing more aggressive PCa [29]. Albertsen et al. [30] showed
that men with Gleason score (GS) 8–10 PCa have a
relatively high probability of dying from PCa within
10 year (12.1%), whereas this risk is minimal for men
with low-grade disease. Therefore, we need to predict
tumor aggressiveness non-invasively. Litjens et al. [31]
found that use of a normalized ADC significantly im-
proved diagnostic accuracy and prediction of cancer ag-
gressiveness, but their assessment was limited to PZ
tumors. The results of this study have demonstrated
that patients with HGPCa (n = 50), the adjusted-PSAD
and nomogram-based risk-score were positively correlated
with the GS of HGPCa (r = 0.455, P = 0.002 and r = 0.509,
P = 0.001, respectively). An accurate noninvasive means of
both detecting and potentially grading tumors is appealing
as a way to enable more-accurate risk stratification of
patients, particularly if different treatment options,
such as radical prostatectomy or focal therapy, are be-
ing considered. In this regard, our results could provide
new tool for predicting the aggressiveness of HGPCa
before biopsy procedure, especially, nomogram-based
risk-score shows relatively strong correlation with GS
of HGPCa in PSA gray zone.
Recently, computer-based medical decision support sys-
tems have been applied to clinical use for medical diagnosis,
decisions, and patient care. Several models—nomograms,
risk groupings, artificial neural networks, support vector
machines —have been developed to help predict a positive
prostate biopsy in men being evaluated for prostate cancer.
Nomograms, artificial neural networks and support vector
machines improved the accuracy of prediction compared
with the individual factors alone. Nomograms are perfect
examples of a predictive application that allows a graphical
representation of variable interactions and a depiction of
their combined effects. Shariat et al. [32] reported that the
nomograms have the highest accuracy and the best dis-
criminating characteristics for predicting outcomes in
prostate cancer patients.
Patients whose cancer is not clinically significant may
be assigned to active surveillance (the lesion is monitored
frequently for signs of progression) instead of treatment.
In our clinical practice, there is also great potential benefit
in the use of mp-MRI for monitoring AS rather than
biopsies. As the process of mp-MRI becomes less inva-
sive, greater acceptance amongst patients may follow.
Furthermore, with the reliability of mp-MRI to image
the entire prostate, it is feasible that patients will feel
further reassured that they did not miss any high-grade
cancer.
We acknowledge the following limitations. As with
any retrospective study, there is risk for selection bias.
On mp-MRI we analysed the index lesion, defined as the
largest most likely to be cancerous area, this might have
been a source of bias in our results. In addition, as men-
tioned previously, we haven’t compare our new model
with other classifiers (e.g., ANN and SVM) in the present
study. Finally, our model has not been performed in an ex-
ternal dataset and requires to be tested and verified in
more centers with larger samples.
Conclusion
This study found that the nomogram based mp-MRI for
forecasting HGPCa is effective, which could reduce un-
necessary prostate biopsies in patients with PSA 4–10 ng/ml
and nomogram-based risk-score could provide a more ro-
bust parameter of assessing the aggressiveness of HGPCa in
PSA gray zone. Future research might indicate that add-
itional parameters could further optimize the diagnosis of
HGPCa without contributing to the high unnecessary biopsy
rate.
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